Venture Funding Deals, December 2015
This article was originally published in Start Up
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a monthly review of emerging In Vitro Diagnostic, Medical Device, and Pharmaceutical companies that have received venture funding. This month’s column covers deals announced October through November 2015.
You may also be interested in...
Six $1bn+ alliances were penned in November. Topping the list was a potential $2.7bn deal between Neurocrine Biosciences and Sosei Group for the development and commercialization of candidates containing certain sub-type selective muscarinic M1, M4, or dual M1/M4 receptor agonists discovered by Sosei Heptares and in development for neurological disorders, which Neurocrine intends to study in the treatment of schizophrenia, dementia, and other neuropsychiatric disorders. The company gains exclusive worldwide rights to develop, manufacture, and commercialize the candidates, while Sosei retains the rights to develop M1 agonist programs in Japan in all indications, with Neurocrine receiving co-development and profit share options.
Major medtech deals in November include Coloplast's $2.5bn acquisition of Atos Medical and Alcon's deal for Ivantis.
Six $1bn+ alliances were penned in October. Topping the list was a potential $3.6bn deal between Poseida Therapeutics and Takeda to utilize Poseida's genetic engineering platforms for the research and development of up to eight gene therapies. The collaboration will focus on non-viral in vivo gene therapy programs, including Poseida's preclinical hemophilia A program P-FVIII-101. Poseida will lead research activities up to candidate selection, after which Takeda will assume responsibility for further exclusive global development and commercialization.